• Direct Mouse Genotyping Kit Plus: High-Fidelity Genotyping M

  2026-05-13

  Unlock rapid, purification-free mouse genotyping with the Direct Mouse Genotyping Kit Plus, engineered for seamless DNA extraction and direct PCR amplification. This workflow-optimized solution streamlines transgene detection, knockout validation, and colony management with robust reproducibility and minimal hands-on time.

• Structural and Functional Insights into Oudemansiella raphan

  2026-05-12

  This study systematically characterizes polysaccharides extracted from Oudemansiella raphanipies, highlighting their optimized extraction, detailed structural features, and potent bioactivities. The findings provide a robust foundation for developing functional food additives and prebiotic agents based on these mushroom-derived biopolymers.

• GSK126 EZH2 Inhibitor: Transforming Cancer Epigenetics Workf

  2026-05-12

  GSK126, a selective EZH2 inhibitor available from APExBIO, empowers researchers to dissect PRC2-driven gene silencing and epigenetic regulation in cancer models. This guide details protocol enhancements, troubleshooting advice, and translational insights rooted in the latest mechanistic research on inflammasome activation and lncRNA regulation.

• D-N-Acetylgalactosamine: Technical Use in Brain Glycoprotein

  2026-05-11

  D-N-Acetylgalactosamine is a high-purity, water-soluble metabolite essential for precise analysis of glycoprotein constituents in neurological research. It is not suitable for protocols requiring ethanol solubility or long-term solution storage, making strict adherence to product-specific and workflow parameters necessary for reproducible results.

• BML-277 and Chk2 Inhibition: Transforming DNA Damage Respons

  2026-05-11

  This thought-leadership article explores the mechanistic, experimental, and translational impact of BML-277—a potent and selective Chk2 inhibitor—on DNA damage response research. Building on the seminal cGAS-TRIM41-ORF2p regulatory axis, we contextualize BML-277’s utility in radioprotection of T-cells and precision cancer biology, providing strategic protocol guidance and an outlook that pushes beyond conventional product discussions.

• Patient-Derived Gastric Cancer Assembloids Reveal Stromal Im

  2026-05-10

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations. The model captures tumor microenvironment complexity, revealing stromal-driven modulation of gene expression and drug response, and offers an improved platform for dissecting resistance mechanisms and optimizing personalized therapies.

• Pharmacokinetics of CSBTA in MASH: Systemic and Hepatic Insi

  2026-05-09

  This study elucidates how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in mice, emphasizing the influence of pathological state and dosing regimen on systemic and hepatic exposure. The findings inform tailored dosing strategies for MASLD/MASH interventions and provide mechanistic understanding of transporter and enzyme modulation.

• AP20187: Precision Control of Protein Networks in Cancer & M

  2026-05-08

  Explore the scientific depth of AP20187 as a chemical inducer of dimerization, focusing on its role in dissecting 14-3-3 signaling and regulated cell therapy. This article uniquely bridges molecular innovation with practical assay strategies for advanced gene therapy research.

• Recombinant Annexin V: A Reliable Probe for Apoptotic Membra

  2026-05-08

  This study details the high-yield expression and purification of recombinant polyhistidine-tagged annexin V in E. coli for sensitive detection of phosphatidylserine externalization during apoptosis. The work enables reproducible, quantitative apoptosis assays and informs membrane biology research through robust FITC-conjugation and flow cytometry techniques.

• Rifampin: Applied Workflows for Bacterial Resistance Researc

  2026-05-07

  Rifampin, a gold-standard rifamycin antibiotic, enables targeted inhibition of bacterial transcription for advanced resistance mechanism studies and synthetic biology. This guide delivers actionable workflow enhancements, addresses common troubleshooting challenges, and integrates literature-backed insights for optimal experimental outcomes.

• Bismuth Subsalicylate in GI Disorder Research: Protocols & T

  2026-05-07

  Bismuth Subsalicylate (1,3,2λ2-benzodioxabismin-4-one) is a gold-standard Prostaglandin G/H Synthase 1/2 inhibitor for gastrointestinal disorder research, enabling reproducible inflammation pathway modulation and advanced membrane biology assays. This guide delivers actionable workflow enhancements, troubleshooting strategies, and context-driven protocol parameters to maximize reproducibility in GI and cell viability studies.

• Bifendate (DDB): Optimizing Hepatoprotection and Autophagy I

  2026-05-06

  Bifendate (DDB) stands out as a benchmark hepatoprotection agent, uniquely combining lipid regulation, autophagy inhibition, and CYP3A4 modulation. This guide translates recent mechanistic insights into actionable workflows, troubleshooting, and comparative advantages for both in vitro and in vivo liver research.

• JZL184 and Translational Endocannabinoid Modulation: New Par

  2026-05-06

  This thought-leadership article explores the mechanistic, experimental, and translational landscape of JZL184—a potent monoacylglycerol lipase inhibitor—highlighting actionable strategies for translational neuroscientists. By integrating recent advances in CB1 receptor-mediated signaling and GLT-1 regulation post-traumatic brain injury, we deliver nuanced guidance on optimizing endocannabinoid modulation for neuroprotection, pain, and anxiety research. Unique to this piece is a rigorous comparison against prior workflows, a granular protocol section, and a candid discussion of domain boundaries, setting it apart from conventional product-focused content.

• NSC 87877: Shp2 Inhibitor Workflows for Neuroinflammation Re

  2026-05-05

  NSC 87877 stands out as a selective Shp2 inhibitor, enabling precise dissection of neuroinflammatory and oncogenic signaling pathways. This article bridges advanced mechanistic insight with practical experimental workflows and troubleshooting tips, empowering researchers to unlock the full translational value of NSC 87877.

• Personalized iPSC Platform Guides Therapy for Ultrarare Muta

  2026-05-05

  Sequiera et al. developed a patient-specific iPSC-based drug screening platform for an individual with an ultrarare Leigh-like syndrome. This approach enabled the preclinical assessment of drug safety and efficacy, offering a new paradigm for personalized clinical trial selection in the context of rare genetic diseases.

14788 records 3/986 page Previous Next 12345 下5页 Last page